Drug Trial Radar · NCT00482833
Phase III Trial in Acute Promyelocytic Leukemia Patients
Last checked: Nov 20, 2026Latest source record: Oct 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
276
Actual
Start
Aug 2007
Primary completion
Sep 2012
Study completion Oct 17, 2019
Sponsor
- Lead sponsor
- Gruppo Italiano Malattie EMatologiche dell'AdultoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Study Alliance Leukemia (SAL) Group
- First posted
- Jun 5, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open label, randomised, phase III multicenter trial.
Conditions
- Leukemia
Interventions
arsenic trioxideDrug
Induction Arsenic Trioxide (As2O3=ATO), 0.15 mg/Kg IV over 2 hours daily starting on day 1. ATO will be continued until hematological CR or for a maximum of 60 days. Consolidation ATO, 0.15 mg/Kg IV over 2 hours daily for 5 days every week. Treatment will be continued for 4 weeks on and 4 weeks off, for a total of 4 cycles (last cycle administered on weeks 25 - 28).
idarubicinDrug
Induction Idarubicin, 12 mg/m² on days 2, 4, 6 and 8 by short (20') intravenous infusion . If no hematological CR is achieved by 60 days after start of induction, patient will go off-study. Consolidation 1st cycle Idarubicin, 5 mg/m2/day by short (20') intravenous infusion on days 1, 2, 3, 4. 3rd cycle Idarubicin, 12 mg/m2/day as short (20') intravenous infusion only on day 1.
mercaptopurineDrug
Maintenance therapy 6-Mercaptopurine (6-MP), 50 mg/m2/day orally. The dose will be adjusted according to hematopoietic toxicity during the follow-up period
methotrexateDrug
Maintenance therapy Methotrexate (MTX), 15 mg/m2/weekly intramuscularly. The dose will be adjusted according to toxicity during the follow-up period.
all-trans retinoic acidDrug
Induction ATRA, 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting on day 1. ATRA treatment will be continued until hematological CR and for a maximum of 60 days. Consolidation 1. st cycle ATRA, 45 mg/m2/day, will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15. 2. nd cycle ATRA, 45 mg/m2/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15. 3. rd cycle ATRA, 45 mg/m2/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15. Maintenance therapy ATRA, 45 mg/m2/day orally, for 15 days every three months until a two year period is completed.
all-trans retinoic acid (ATRA)Drug
Induction All-trans retinoic acid (ATRA), 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting on day 1. ATRA treatment will be continued until hematological complete remission (CR, see below for definition) or for a maximum of 60 days. Consolidation ATRA, 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment. Treatment will be administered for 2 weeks on 2 weeks off and for a total of 7 cycles (last cycle administered on weeks 25 - 26).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free survivalTime frame: At maximum 3.5 years from study entry
Locations
110 sites in 3 countries. Site status is shown where the registry gives one.
Universitätsklinik Innsbruck Hämatologie Onkologie
Innsbruck, Austria
Krankenhaus der Barmherzigen Schwestern Linz
Linz, Austria
Universitätsklinik für Innere Medizin III Salzburg
Salzburg, Austria
Klinikum Bayreuth GmbH
Bayreuth, Germany
Charité Campus Benjamin Franklin Berlin
Berlin, Germany
Städt. Kliniken Bielefeld gem. GmbH
Bielefeld, Germany
Universitätsklinikum Bonn
Bonn, Germany
Ev. Diakonie-Krankenhaus gGmbH Bremen
Bremen, Germany
Klinikum Bremen-Mitte gGmbH
Bremen, Germany
Klinikum Chemnitz gGmbH
Chemnitz, Germany
Universitätsklinikum C. G. Carus Dresden
Dresden, Germany
Katholisches Klinikum Duisburg St. Johannes Hospital
Duisburg, Germany
Universitätsklinikum Düsseldorf
Düsseldorf, Germany
Uniklinikum Erlangen
Erlangen, Germany
Kliniken Essen Süd, Ev. Krankenhaus Essen-Werden gGmbH
Essen, Germany
Universitätsklinikum Essen
Essen, Germany
Uniklinik Frankfurt/Main
Frankfurt am Main, Germany
Städtische Kliniken Frankfurt a. M.-Höchst
Frankfurt/a. M. -Höchst, Germany
Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
Klinikum Fulda
Fulda, Germany
Universitätsklinikum Gießen und Marburg Gießen
Giessen, Germany
Universitätsklinikum Göttingen
Göttingen, Germany
Asklepios Klinik Hamburg Altona
Hamburg, Germany
Asklepios Klinik St. Georg Hamburg
Hamburg, Germany
Universitätsklinikum Hamburg Eppendorf
Hamburg, Germany
St. Marien-Hospital gem. GmbH Hamm
Hamm, Germany
Medizinische Hochschule Hannover
Hanover, Germany
Universitätsklinikum Heidelberg
Heidelberg, Germany
St. Bernward Krankenhaus Hildesheim
Hildesheim, Germany
Universitätsklinikum des Saarlandes Homburg/Saar
Homburg, Germany
Klinik für Knochenmarktransplantation und Hämatologie Idar-Oberstein
Idar-Oberstein, Germany
Westpfalz-Klinikum GmbH Kaiserslautern
Kaiserslautern, Germany
Caritas-Krankenhaus Lebach
Lebach, Germany
Klinikum Lippe Lemgo
Lippe, Germany
Uniklinikum Lübeck
Lübeck, Germany
Klinikum der Johannes Gutenberg Universität Mainz
Mainz, Germany
Universitätsklinikum Gießen und Marburg GmbH Marburg
Marburg, Germany
Carl-von-Basedow-Klinikum Merseburg
Merseburg, Germany
Johannes Wesling Klinikum Minden
Minden, Germany
Klinikum rechts der Isar (München)
München, Germany
Showing 40 of 110 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.